User profiles for "author:C Caldas"
Carlos CaldasUniversity of Cambridge Verified email at cruk.cam.ac.uk Cited by 114178 |
Liquid biopsies come of age: towards implementation of circulating tumour DNA
…, F Mouliere, JD Brenton, C Caldas… - Nature Reviews …, 2017 - nature.com
Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …
Patient-derived xenograft models: an emerging platform for translational cancer research
Recently, there has been an increasing interest in the development and characterization of
patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly …
patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly …
Toward understanding and exploiting tumor heterogeneity
The extent of tumor heterogeneity is an emerging theme that researchers are only beginning
to understand. How genetic and epigenetic heterogeneity affects tumor evolution and …
to understand. How genetic and epigenetic heterogeneity affects tumor evolution and …
Signatures of mutational processes in human cancer
All cancers are caused by somatic mutations; however, understanding of the biological
processes generating these mutations is limited. The catalogue of somatic mutations from a …
processes generating these mutations is limited. The catalogue of somatic mutations from a …
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
We analysed whole-genome sequences of 560 breast cancers to advance understanding of
the driver mutations conferring clonal advantage and the mutational processes generating …
the driver mutations conferring clonal advantage and the mutational processes generating …
The landscape of cancer genes and mutational processes in breast cancer
All cancers carry somatic mutations in their genomes. A subset, known as driver mutations,
confer clonal selective advantage on cancer cells and are causally implicated in …
confer clonal selective advantage on cancer cells and are causally implicated in …
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Primary triple-negative breast cancers (TNBCs), a tumour type defined by lack of oestrogen
receptor, progesterone receptor and ERBB2 gene amplification, represent approximately …
receptor, progesterone receptor and ERBB2 gene amplification, represent approximately …
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
Oestrogen receptor-α (ER) is the defining and driving transcription factor in the majority of
breast cancers and its target genes dictate cell growth and endocrine response, yet genomic …
breast cancers and its target genes dictate cell growth and endocrine response, yet genomic …
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer
CpG island hypermethylation and global genomic hypomethylation are common epigenetic
features of cancer cells. Less attention has been focused on histone modifications in cancer …
features of cancer cells. Less attention has been focused on histone modifications in cancer …
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
…, J Hadfield, D Bentley, TM Chin, JD Brenton, C Caldas… - Nature, 2013 - nature.com
Cancers acquire resistance to systemic treatment as a result of clonal evolution and
selection,. Repeat biopsies to study genomic evolution as a result of therapy are difficult …
selection,. Repeat biopsies to study genomic evolution as a result of therapy are difficult …